PT2900254T - Alfa-1-microglobulina para a sua utilização no tratamento de doenças relacionadas com mitocôndrias - Google Patents
Alfa-1-microglobulina para a sua utilização no tratamento de doenças relacionadas com mitocôndrias Download PDFInfo
- Publication number
- PT2900254T PT2900254T PT137599957T PT13759995T PT2900254T PT 2900254 T PT2900254 T PT 2900254T PT 137599957 T PT137599957 T PT 137599957T PT 13759995 T PT13759995 T PT 13759995T PT 2900254 T PT2900254 T PT 2900254T
- Authority
- PT
- Portugal
- Prior art keywords
- deficiency
- aim
- mitochondrial
- microglobulin
- cells
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1722—Plasma globulins, lactoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Nutrition Science (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201270538 | 2012-09-05 | ||
| DKPA201270557 | 2012-09-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2900254T true PT2900254T (pt) | 2016-10-18 |
Family
ID=49162118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT137599957T PT2900254T (pt) | 2012-09-05 | 2013-09-04 | Alfa-1-microglobulina para a sua utilização no tratamento de doenças relacionadas com mitocôndrias |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10226507B2 (enExample) |
| EP (1) | EP2900254B1 (enExample) |
| JP (2) | JP2015533790A (enExample) |
| KR (1) | KR20150047510A (enExample) |
| CN (1) | CN104661673A (enExample) |
| AU (1) | AU2013311714C1 (enExample) |
| BR (1) | BR112015003957A2 (enExample) |
| CA (1) | CA2881321A1 (enExample) |
| DK (1) | DK2900254T3 (enExample) |
| EA (1) | EA028963B1 (enExample) |
| ES (1) | ES2599034T3 (enExample) |
| HR (1) | HRP20161364T1 (enExample) |
| HU (1) | HUE030559T2 (enExample) |
| IN (1) | IN2015DN00515A (enExample) |
| MX (1) | MX357656B (enExample) |
| NZ (1) | NZ629621A (enExample) |
| PL (1) | PL2900254T3 (enExample) |
| PT (1) | PT2900254T (enExample) |
| SG (1) | SG11201500669SA (enExample) |
| WO (1) | WO2014037390A1 (enExample) |
| ZA (1) | ZA201500547B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016204360A (ja) * | 2015-02-25 | 2016-12-08 | エー１エム ファーマ エービーＡ１Ｍ Ｐｈａｒｍａ ＡＢ | 放射性核種療法における腎臓の保護に用いるためのアルファ−１−ミクログロブリン |
| CA3014850A1 (en) * | 2016-02-25 | 2017-08-31 | A1M Pharma Ab | Alpha-1-microglobulin for use in the protection of kidneys in connection with use of contrast media |
| US10981963B2 (en) * | 2016-03-18 | 2021-04-20 | Guard Therapeutics International AB | Alpha-1-microglobulin derived proteins and their use |
| GB2566516A (en) | 2017-09-15 | 2019-03-20 | Univ Oxford Innovation Ltd | Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria |
| CN109867717A (zh) * | 2019-04-01 | 2019-06-11 | 山西瑞亚力生物技术有限公司 | 一种血浆中α1微球蛋白的提取方法 |
| CN110452980B (zh) * | 2019-09-23 | 2023-07-28 | 武汉儿童医院 | 一种线粒体脑肌病诊断试剂盒及应用 |
| US20220362293A1 (en) * | 2019-09-25 | 2022-11-17 | Cytegen Corp. | Treatment of Mitochondrial Deficits and Age-Related Diseases Using Blood Products |
| CN115575646B (zh) * | 2022-11-21 | 2023-04-28 | 四川大学华西医院 | 一种代谢标志物组在制备预测癫痫发作的试剂盒中的用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004292775A1 (en) * | 2003-11-26 | 2005-06-09 | Sanofi-Aventis Deutschland Gmbh | Tubular proteinuria as an indicator for elevated cardiovascular risk |
| KR101454013B1 (ko) * | 2007-02-12 | 2014-11-12 | 에이원엠 파마 에이비 | 자간전증의 진단 및 치료 |
| SI2300614T1 (sl) * | 2008-02-04 | 2016-02-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Metode in sestavki za zdravljenje mitohondrijskih motenj |
| WO2010006809A2 (en) | 2008-07-18 | 2010-01-21 | Akerstroem Bo | Medical use of the radical scavenger and antioxidant alpha-1-microglobulin |
-
2013
- 2013-09-04 PT PT137599957T patent/PT2900254T/pt unknown
- 2013-09-04 IN IN515DEN2015 patent/IN2015DN00515A/en unknown
- 2013-09-04 US US14/423,260 patent/US10226507B2/en not_active Expired - Fee Related
- 2013-09-04 SG SG11201500669SA patent/SG11201500669SA/en unknown
- 2013-09-04 WO PCT/EP2013/068270 patent/WO2014037390A1/en not_active Ceased
- 2013-09-04 JP JP2015530375A patent/JP2015533790A/ja active Pending
- 2013-09-04 CA CA2881321A patent/CA2881321A1/en not_active Abandoned
- 2013-09-04 EP EP13759995.7A patent/EP2900254B1/en not_active Not-in-force
- 2013-09-04 AU AU2013311714A patent/AU2013311714C1/en not_active Ceased
- 2013-09-04 DK DK13759995.7T patent/DK2900254T3/en active
- 2013-09-04 KR KR1020157005748A patent/KR20150047510A/ko not_active Ceased
- 2013-09-04 HU HUE13759995A patent/HUE030559T2/en unknown
- 2013-09-04 MX MX2015002604A patent/MX357656B/es active IP Right Grant
- 2013-09-04 ES ES13759995.7T patent/ES2599034T3/es active Active
- 2013-09-04 BR BR112015003957A patent/BR112015003957A2/pt not_active Application Discontinuation
- 2013-09-04 CN CN201380043567.0A patent/CN104661673A/zh active Pending
- 2013-09-04 NZ NZ629621A patent/NZ629621A/en not_active IP Right Cessation
- 2013-09-04 EA EA201590503A patent/EA028963B1/ru not_active IP Right Cessation
- 2013-09-04 HR HRP20161364TT patent/HRP20161364T1/hr unknown
- 2013-09-04 PL PL13759995T patent/PL2900254T3/pl unknown
-
2015
- 2015-01-23 ZA ZA2015/00547A patent/ZA201500547B/en unknown
-
2018
- 2018-08-24 JP JP2018157394A patent/JP2018203756A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015003957A2 (pt) | 2017-08-08 |
| MX357656B (es) | 2018-07-18 |
| KR20150047510A (ko) | 2015-05-04 |
| EP2900254A1 (en) | 2015-08-05 |
| US10226507B2 (en) | 2019-03-12 |
| HK1210585A1 (en) | 2016-04-29 |
| EP2900254B1 (en) | 2016-08-03 |
| ZA201500547B (en) | 2017-09-27 |
| EA201590503A1 (ru) | 2015-06-30 |
| HRP20161364T1 (hr) | 2016-12-16 |
| AU2013311714A1 (en) | 2015-03-12 |
| PL2900254T3 (pl) | 2017-02-28 |
| AU2013311714B2 (en) | 2017-10-12 |
| HUE030559T2 (en) | 2017-05-29 |
| WO2014037390A1 (en) | 2014-03-13 |
| NZ629621A (en) | 2015-09-25 |
| US20150258171A1 (en) | 2015-09-17 |
| CA2881321A1 (en) | 2014-03-13 |
| MX2015002604A (es) | 2015-06-10 |
| IN2015DN00515A (enExample) | 2015-06-26 |
| JP2015533790A (ja) | 2015-11-26 |
| EA028963B1 (ru) | 2018-01-31 |
| SG11201500669SA (en) | 2015-02-27 |
| JP2018203756A (ja) | 2018-12-27 |
| ES2599034T3 (es) | 2017-01-31 |
| CN104661673A (zh) | 2015-05-27 |
| AU2013311714C1 (en) | 2018-01-25 |
| DK2900254T3 (en) | 2016-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2599034T3 (es) | Alfa-1-microglobulina para su uso en el tratamiento de enfermedades relacionadas con mitocondrias | |
| Ding et al. | The R172W mutation in peripherin/rds causes a cone–rod dystrophy in transgenic mice | |
| Britti et al. | Frataxin‐deficient neurons and mice models of Friedreich ataxia are improved by TAT‐MTS cs‐FXN treatment | |
| JP2020055866A (ja) | 種々の疾患を処置するためのｊｎｋシグナル伝達経路の新規の細胞透過性ペプチド阻害剤の使用 | |
| Hughes et al. | Inhibition of storage pathology in prenatal CLN5-deficient sheep neural cultures by lentiviral gene therapy | |
| BRPI0211200B1 (pt) | Peptídeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células | |
| CN104023736A (zh) | Jnk信号转导途径的细胞-可渗透肽抑制剂用于治疗干眼综合征的用途 | |
| Cederlund et al. | Vitreous levels of oxidative stress biomarkers and the radical-scavenger α1-microglobulin/A1M in human rhegmatogenous retinal detachment | |
| Lee et al. | Prohibitin as an oxidative stress biomarker in the eye | |
| ES2552587B1 (es) | Péptido derivado de socs1 para su uso en complicaciones crónicas de la diabetes | |
| ES2896734T3 (es) | Proteínas novedosas derivadas de la alfa-1-microglobulina y su uso | |
| Formichi et al. | Analysis of opa1 isoforms expression and apoptosis regulation in autosomal dominant optic atrophy (ADOA) patients with mutations in the opa1 gene | |
| ES2868354T3 (es) | Péptido Naktide para el tratamiento de la obesidad | |
| HK1210585B (en) | Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases | |
| Yang et al. | Glial cells activation potentially contributes to the upregulation of stromal cell-derived factor-1α after optic nerve crush in rats | |
| Petese et al. | Are Lysosomes Potential Therapeutic Targets for Parkinson’s Disease? | |
| Jones | The role of optic atrophy 1 (OPA1) in the evolution of brain damage after neonatal hypoxic-ischaemic insult | |
| Li et al. | Protective effect of apelin-13 in lens epithelial cells via inhibiting oxidative stress-induced apoptosis | |
| Vijayasarathy et al. | Organization and molecular interactions of retinoschisin in photoreceptors | |
| Alassaf | Pregnancy Associated Plasma Protein-aa Is a Novel Regulator of Neuron Survival | |
| Faber et al. | Gene augmentation of LCA5-Leber congenital amaurosis ameliorates bulge region defects of the photoreceptor ciliary axoneme | |
| US20190099468A1 (en) | Method to protect and seal the ocular surface | |
| KR101481741B1 (ko) | Ⅰｇｆ１을 이용한 변형 프리온 단백질에 의해 유도되는 세포자멸사의 억제방법 | |
| KR20240159668A (ko) | Prdx3를 유효성분으로 포함하는 미토콘드리아 관련 질환 예방 또는 치료용 조성물 및 이의 용도 | |
| CN121127256A (zh) | 作为有效成分包含Prdx3的线粒体相关疾病预防或治疗用组合物及其用途 |